Establishment Labs (NASDAQ:ESTA) Price Target Raised to $47.00

Establishment Labs (NASDAQ:ESTA - Free Report) had its price objective upped by Citigroup from $38.00 to $47.00 in a report issued on Wednesday morning,Benzinga reports. They currently have a neutral rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Establishment Labs from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th. Needham & Company LLC reissued a "buy" rating and issued a $48.00 price target on shares of Establishment Labs in a research report on Friday, June 13th. Finally, BTIG Research began coverage on shares of Establishment Labs in a research report on Friday, May 16th. They issued a "buy" rating and a $62.00 price target for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $51.80.

Establishment Labs Stock Up 3.7%

Shares of NASDAQ:ESTA traded up $1.67 during trading on Wednesday, hitting $46.73. The company's stock had a trading volume of 8,478 shares, compared to its average volume of 476,492. The business has a 50 day moving average price of $37.68 and a two-hundred day moving average price of $36.94. The company has a market capitalization of $1.35 billion, a PE ratio of -15.07 and a beta of 0.80. The company has a debt-to-equity ratio of 5.72, a quick ratio of 2.05 and a current ratio of 3.36. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $52.41.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.13. The business had revenue of $41.38 million during the quarter, compared to the consensus estimate of $41.15 million. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The company's quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.58) earnings per share. As a group, research analysts expect that Establishment Labs will post -2.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ESTA. Toronto Dominion Bank acquired a new position in shares of Establishment Labs during the fourth quarter worth about $24,879,000. Brown Advisory Inc. increased its stake in shares of Establishment Labs by 23.1% during the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock worth $107,729,000 after acquiring an additional 438,057 shares during the period. Capital Research Global Investors increased its stake in shares of Establishment Labs by 29.3% during the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after acquiring an additional 433,484 shares during the period. Voya Investment Management LLC increased its stake in shares of Establishment Labs by 7,249.5% during the fourth quarter. Voya Investment Management LLC now owns 408,262 shares of the company's stock worth $18,809,000 after acquiring an additional 402,707 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Establishment Labs by 96.9% during the fourth quarter. Millennium Management LLC now owns 711,691 shares of the company's stock worth $32,788,000 after acquiring an additional 350,213 shares during the period. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.